Intravenous immunoglobulin therapy (IVIG) is a critical treatment modality in the management of a spectrum of immunodeficiencies, autoimmune disorders, and inflammatory conditions. Derived from pooled ...

Immunoglobulin replacement therapy (IgRT) represents a pivotal intervention in managing secondary immunodeficiency, a complication arising from treatments or underlying conditions that impair the body ...

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, ...

Findings showed after 52 weeks, significant improvements in 2MWD and 6MWD were seen with Flebogamma 5% DIF 1mg/kg compared with placebo. Topline data were announced from a phase 2/3 trial evaluating ...

Plasma-derived immunoglobulin replacement therapy (IRT) is one of the mainstays of supportive management for many inborn errors of immunity, primarily those affecting the adaptive immune system which ...

The Accreditation Commission for Health Care (ACHC) has partnered with the Immunoglobulin National Society (IgNS) to launch the Distinction in Immunoglobulin Therapy.

Intravenous immunoglobulin (IVIG) is donor-derived antibodies used in myasthenia gravis (MG) for fast symptom control. It’s used for flares, maintenance, bridging slower therapies, or pre-surgery ...

Immunoglobulin replacement therapy in CLL patients does not reduce serious infection risk, despite increased usage over 14 years. The study found higher infection rates during immunoglobulin therapy ...

Treatment with immunoglobulin replacement therapy is often used to boost antibody levels in an effort to reduce infection risk. "Many of the studies supporting the use of immunoglobulins to reduce ...

Please provide your email address to receive an email when new articles are posted on . Immunoglobulin replacement therapy triggered severe neuropathy. A 4,200 U dose ...

The survey process was led by Amerita’s Director of Quality and Accreditation Kayla Ortlip, PharmD, IgCP, MBA. It resulted in the company receiving this distinction with zero deficiencies, ...